Millendo Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of new treatments for endocrine diseases with significant unmet medical needs. The company's primary focus is on creating distinct and transformative treatments where current therapies are insufficient. Millendo is currently working on advancing its lead candidate drug, MLE-301, for the treatment of vasomotor symptoms in women experiencing menopause.